🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "major milestone" in the battle against increasingly resistant strains of the pathogen, according to health experts.

A Worldwide Health Concern

Gonorrhoea infections are escalating around the world, with data suggesting in excess of 82 million new cases annually. Notably increased rates are observed in the African continent and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the reality of growing infection rates, escalating drug resistance and the very limited available drugs at this time.”

Public health authorities are increasingly worried about the surge in treatment-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance found that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Clearance

Zoliflodacin, also known as Nuzolvence, was approved by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts believe that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the drugmaker GlaxoSmithKline, was also approved in close succession. This treatment, which is also used to treat urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This authorization marks a significant shift in the treatment of highly resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Clinical Trial Outcomes and Worldwide Availability

According to findings released by a major medical journal, zoliflodacin successfully treated more than 90% of uncomplicated infections. This places it at an comparable level with the current standard treatment, which uses a dual-drug approach. The study enrolled over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the rights to license and sell the drug in many low-income and middle-income countries.

Medical professionals directly involved have shared hope. Access to a single-dose, oral treatment like this is hailed as a "critical tool" for managing the epidemic. This is deemed essential to alleviate the strain of the disease for people and to stop the proliferation of highly drug-resistant gonorrhoea globally.